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Abstract
A patient specific quality assurance (QA) should detect errors that originate
anywhere in the treatment planning process. However, the increasing complexity
of treatment plans has increased the need for improvements in the accuracy of
the patient specific pretreatment verification process. This has led to the utilization
of higher resolution QA methods such as the electronic portal imaging device
(EPID) as well as MLC log files and it is important to know the types of errors
that can be detected with these methods. In this study, we will compare the abil-
ity of three QA methods (Delta4, MU-EPID, Dynalog QA) to detect specific
errors. Multileaf collimator (MLC) errors, gantry angle, and dose errors were intro-
duced into five volumetric modulated arc therapy (VMAT) plans for a total of 30
plans containing errors. The original plans (without errors) were measured five
times with each method to set a threshold for detectability using two standard
deviations from the mean and receiver operating characteristic (ROC) derived lim-
its. Gamma passing percentages as well as percentage error of planning target vol-
ume (PTV) were used for passing determination. When applying the standard 95%
pass rate at 3%/3 mm gamma analysis errors were detected at a rate of 47, 70,
and 27% for the Delta4, MU-EPID and Dynalog QA respectively. When using
thresholds set at 2 standard deviations from our base line measurements errors
were detected at a rate of 60, 30, and 47% for the Delta4, MU-EPID and Dynalog
QA respectively. When using ROC derived thresholds errors were detected at a
rate of 60, 27, and 47% for the Delta4, MU-EPID and Dynalog QA respectively.
When using dose to the PTV and the Dynalog method 11 of the 15 small MLC
errors were detected while none were caught using gamma analysis. A combina-
tion of the EPID and Dynalog QA methods (scaling Dynalog doses using EPID
images) matches the detection capabilities of the Delta4 by adding additional com-
parison metrics. These additional metrics are vital in relating the QA measurement
to the dose received by the patient which is ultimately what is being confirmed.
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1 | INTRODUCTION
Pretreatment quality assurance (QA) of an intensity modulated radio-
therapy (IMRT) plan is essential in preventing errors from propagat-
ing throughout the course of treatment. The rate and frequency of
potential errors have increased as treatments shifted from 3D con-
formal to IMRT and volumetric modulated arc therapy (VMAT).
Numerous studies have shown the need for QA methods to be
appropriate for the treatment technology used.1 Therefore, aware-
ness of the error detection capabilities of an IMRT QA system used
in clinical environment is important for optimum delivery of complex
treatments.
Two-dimensional (2D) diode arrays are commonly used for
patient-specific IMRT QA. Dose distributions are first calculated on
the phantom geometry in the treatment planning system (TPS) and
then delivered and measured at the treatment machine. A very com-
mon method to quantitatively compare measured and calculated dose
distributions is the concept of gamma index introduced by Low et al.2
This approach represents the minimum distance between the mea-
surement and calculation points compared against acceptance criteria
for distance-to-agreement (DTA) and percentage dose differences (%
DD). The effectiveness of the gamma index tool for IMRT QA has
been investigated3–9 with special emphasis on the sensitivity of differ-
ent gamma criteria to positioning errors.5 The results of these investi-
gations have shown that the gamma index can fail to detect errors
that may have a significant biological impact. Fundamentally, the
patient-specific QA should be linked with treatment outcomes.10
Dose volume histogram (DVH) based analysis of IMRT QA have
proven the effectiveness of this modality while also showing that
the gamma index values may have low correlation with the clinical
impact of the errors.4,11 For this reason, in this study both the
gamma index and DVH based metrics will be used to evaluate error
detection capabilities of three IMRT patient specific QA methods.
Method 1 uses the Delta4 (Scandidos, Madison, WI, USA) which is
our current clinical IMRT QA system. Method 2 is an in-house
MatLab program (MU-EPID) (The MathWorks, Inc., Natick, MA, USA)
which utilizes the EPID for the purpose of patient specific IMRT QA
measurements.12 MU-EPID has previously been validated as an
IMRT-QA tool by comparison with the Delta4.12,13 Method 3 uses
Varian (Varian Medical Systems, Inc, Palo Alto, CA, USA) MLC log
files (Dynalogs) and an in-house MatLab program (Dynalog QA) to
import the recorded machine parameters into the treatment planning
system (TPS) for patient dose recalculation.
The purpose of this study is to investigate the ability of each
method mentioned above to detect intentional errors. It is important
for the physicists performing IMRT QA and analyzing the results to
know the limitations of the measuring and analysis system. Further-
more, the sensitivity of error detection using two independent meth-
ods is examined.
2 | METHODS AND MATERIALS
2.A | Patient population
Our patient population consisted of five VMAT patients, four pros-
tate cancer patients, and one rectal cancer patient. These disease
sites were chosen because of the similar organs-at-risk (OAR)
involved in the treatments so direct comparison of DVH values is
possible. All VMAT plans were designed using Pinnacle v9.8 (Philips
Radiation Oncology Systems, Fitchburg, WI, USA). Each VMAT plan
consisted of two full arcs with the isocenter at the center of the
planning target volume (PTV). All contours for the target and the
OARs were outlined by the same physician. The optimized plans
were then copied and calculated on the Delta4 phantom using the
same monitor units (MU’s) as the actual treatment plan. The patient-
specific VMAT QA plans were exported using DICOM to the Scandi-
dos software for comparison against the measurements. Table 1
shows the monitor units (MUs) and beam energies for each of the
patient plans.
2.B | Baseline measurements
All plans were optimized and delivered on a Novalis Tx (Varian Medi-
cal Systems) linear accelerator equipped with an HD-120 MLC and
an aS1000 EPID. To determine the threshold of detectability of our
methods, we first established a baseline by measuring all treatment
plans five (n = 5) consecutive times with each QA method and per-
formed gamma index analysis of each. Each treatment plan was
delivered on the Novalis Tx consecutively on the same day to mini-
mize linac output and EPID response variation. The mean gamma
index passing percentage rate for each plan using 3%/3 mm, 2%/
2 mm, and 1%/1 mm tolerances was used as a reference standard.
Using the baseline statistics, a detection threshold was set at two
TAB L E 1 Patient parameters.
Site MUs Energy
Prostate 646 10 MV
Prostate 542 10 MV
Rectum 516 6 MV
Prostate 1322 10 MV
Prostate 648 6 MV
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standard deviations from the mean. The baseline measurements also
provide values for D2 and D98 of the PTV to be used for determina-
tion of detection thresholds. Tables 2 and 3 show the resulting
gamma index and the average deviation of D2 and D98.
2.C | Errors
A total of six different versions of the original treatment were pro-
duced for each patient plan, each version containing a different type
of error listed in Table 4. These “deliberate” errors represent typical
errors that could occur during treatment. (a) Dose errors were simu-
lated by increasing the overall delivered MU by 3%. (b) Gantry angle
errors were introduced by increasing the gantry angle by 1 degree at
each control point. (c) A 2 mm MLC shift was introduced to the cen-
ter leaf pair at each control point. (d) The same leaves were also
shifted by 4 mm in a separate plan. (e) A plan was created in which
all MLC pairs were shifted by 1 mm at every control point, and (f)
another plan in which all MLC leaves were shifted away from the
central axis by 1 mm. Such shifts of all MLC leaves were chosen to
represent an MLC calibration error. The plans were modified to
include the errors above, using a MatLab script and the original
DICOM RT file for each patient. Figure 1 shows a visual representa-
tion of the MLC errors.
2.D | Receiver operating characteristic (ROC)
analysis
ROC analysis provides tools to identify optimal models and to dis-
card suboptimal ones. ROC analysis is to cost/benefit analysis of
diagnostic decision-making. An ROC curve is generated by
quantifying true positives (errors detected) and false positives (de-
tections that are not errors) and plotting their respective probabili-
ties. To investigate the detectability of each method, the number
of true positives and false positives were determined for many
different thresholds (Fig. 2) for the gamma criteria of 3%/3 mm,
2%/2 mm, and 1%/1 mm. These data were used to generate ROC
curves (Fig. 3). For each method, results are presented for the
gamma criteria that resulted in the largest area under the ROC
curve and the threshold chosen was that which had the highest
true positive to false positive ratio. If a threshold had zero false
positives the ratio was just the number of true positives. Thresh-
olds for the PTV dose analysis were determined using this method
as well.
2.E | Scandidos delta4
The treatment plans containing “known” errors, for each patient,
were measured using the Delta4 detector array, following our insti-
tutional procedures. Gamma analysis of the Delta4 measurements
was performed with the Delta4 software. The phantom position was
then optimized using the Delta4 software option to correct for
phantom set up errors. The gamma index was then calculated for
the criteria mentioned previously in the Baseline Measurements
section.
2.F | Epid
The IMRT QA plans were delivered without a phantom in the beam
and the fluence maps were collected by the EPID. The EPID images
were processed through the MU-EPID software for all patients to con-
vert them into an optical density matrix (ODM) and imported into Pin-
nacle TPS. First, a pixel-intensity-to-MU conversion factor was
determined by delivering 100 MU using a 10 9 10 cm2 field to the
EPID prior to each IMRT QA session. An average pixel intensity is
taken over a region of the calibration image corresponding to the cen-
tral axis of the beam. This pixel value per MU factor was then used to
convert IMRT QA image intensities to MU values that were applied to
the ODMs. The IMRT QA images were then corrected for the variation
in response across the EPID by applying a correction matrix. The cor-
rection matrix was created by comparing dose resulting from an ideal
TAB L E 2 Baseline gamma data for all methods and gamma criteria.
Delta4 SD Average
3%/3 mm 1.01 98.81%
2%/2 mm 7.42 92.97%
1%/1 mm 15.52 70.76%
Dynalog
3%/3 mm 0.18 99.86%
2%/2 mm 0.45 99.56%
1%/1 mm 1.31 97.89%
MU-EPID
3%/3 mm 1.76 94.03%
2%/2 mm 2.90 82.37%
1%/1 mm 3.03 54.33%
TAB L E 3 Baseline dosimetric data for the Dynalog and MU-EPID
methods.
Dynalog SD Average dev
D2 0.37 0.44%
D98 0.66 1.67%
MU-EPID SD Average dev
D2 1.34 5.20%
D98 1.40 9.58%
TAB L E 4 Errors introduced into VMAT plans.
Errors Magnitude
Dose 3%
Gantry rotation 1 degree
Leaf pair shift 2 mm
Leaf pair shift 4 mm
All leaves shifted 1 mm
MLC banks widened 1 mm
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fluence to dose resulting from the EPID detected fluence. Using the
ODMs, a plan was calculated in Pinnacle using the same patient geom-
etry and contours. The DVHs for each ODM based plan were then cal-
culated using the treatment planning system. The doses calculated
using each field’s ODM in Pinnacle for each patient plan were then
exported to the MU EPID software. Dose distributions and DVHs for
the initial plans and the recalculated ones (using the EPID based ODM)
were compared for each plan.
2.G | Dynalog
The Dynalog files were recorded during the EPID image acquisitions.
The MLC positions, gantry angles and collimator angles were col-
lected and used to replace the respective ones of the original plans
and imported back to Pinnacle TPS. The treatment plans were then
recalculated using the dynalog recorded parameters for each patient.
The resulting dose distributions were exported and processed using
MatLab to obtain the same dosimetric data as with the plans calcu-
lated using ODMs generated from EPID images. Dynalog files do not
contain information on the actual number of monitor units delivered,
therefore EPID images were used in conjunction with MU values
derived from the same pixel-intensity-to-MU conversion algorithm
used in the EPID method.
2.H | Gamma index analysis
Gamma index analysis was performed in Verisoft (PTW, Freiburg, Ger-
many) for the MU-EPID and Dynalog QA methods while the Scandidos
Delta4 software was used for the Delta4 measurements. A dose grid
resolution of 0.3 cm was used for MU-EPID and Dynalog QA dose
50
55
60
65
70
75
80
85
90
95
100
Dose MLC Widen Gantry MLC 2 MLC 4 MLC ALL Baselines
Ga
m
m
a 
Pa
ss
in
g 
%
ROC
F I G . 2 . Example of determination of
ROC curves.
(a)
(b) (d)
(c) (e)
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F I G . 3 . ROC curves for all three methods.
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distributions and 3D gamma analysis was performed. The 2D gamma
analysis used in the Delta4 software compares dose measured at each
diode (0.5 cm resolution in the center 6 cm 9 6 cm area and 1 cm
resolution elsewhere) with the dose calculated by the TPS. A total of
55 treatment plans were analyzed with each method, 30 error contain-
ing plans and 25 plans without errors to establish a baseline. The
detection of errors was evaluated at the standard passing gamma per-
centages 90% at 3%/3 mm, 80% at 2%/2 mm, and 50% at 1%/1 mm.
The passing criteria for 2%/2 mm and 1%/1 mm were derived by
matching the number of detected errors at the standard 90% passing
threshold. Error detection was also evaluated at passing thresholds set
at two standard deviations (SD) from the mean of the baseline and at
the percentage determined from ROC analysis.
3 | RESULTS
3.A | Gamma index analysis
At 3%/3 mm and the ROC derived passing gamma cut-off, the
Delta4 (96.9%) detected 18 of 30 errors with 1 false positive, the
EPID (90%) detected 8 of 30 errors with 0 false positives and the
MLC log file method (99.4%) detected 14 of 30 errors with 0 false
positives. At 3%/3 mm and the 2 SD passing gamma cut-off, the
Delta4 (96.8%) detected 18 of 30 errors with one false positive, the
EPID (90.5%) detected 9 of 30 errors with one false positive and
the MLC log file method (99.5%) detected 14 of 30 errors with four
false positives. Evaluation of gamma at 3%/3 mm yielded better
ROC curves than 2%/2 mm or 1%/1 mm. This is due to the
increase in the number of false positives with the more strict
criteria. Bar graphs showing the number of errors detected along
with the false positives (pink) using gamma analysis are shown in
Figs. 4–6.
3.B | PTV dose
The dose comparison metrics between the plans containing errors
and the original plans were the absolute percent difference of D2
and D98 of the PTV. The threshold for detection of errors based on
D2 and D98 was determined by ROC analysis. Using D2 of the PTV
and a detection threshold of 0.8% the Dynalog method detected 20
of 30 errors with five false positives. However, false positives were
detected for only one patient with all five baseline measurements
having PTV D2 deviations of greater than 1.4%. The maximum PTV
D2 deviation for all other baseline measurements of the other four
patients was 0.3%. Using a detection threshold of 6%, the EPID
method detected 14 of 30 errors with six false positives. Finally,
using D98 of the PTV and a detection threshold of 5.2% the Dynalog
method detected 13 of 30 errors with three false positives, and with
a detection threshold of 16% the EPID method detected 3 of 30
errors with zero false positives. A bar graph depicting the errors
detected and the number of false positives using D2 and D98 is
shown in Fig. 7.
F I G . 4 . Bar graphs of errors detected by
the Delta4 at 3%/3 mm, 2%2/ mm, and
1%1 mm.
F I G . 5 . Bar graphs of errors detected by
MU-EPID at 3%/3 mm, 2%2/ mm, and 1%
1 mm.
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4 | DISCUSSION
4.A | Gamma analysis
4.A.1 | MU-EPID
The EPID showed limited error detection capabilities mainly due to
the geometry (loss of gantry angle information) and the over
response to scattered radiation. Corrections for the variation in
response across the EPID were applied, however, the correction is
not able to account for scatter radiation which will largely depend
on the plan being delivered. These deficiencies limit the effective-
ness of the EPID as a comprehensive IMRT QA tool. The EPID
does, however, provide a physical “measurement” that can be use-
ful. The pixel intensity to MU conversion factor derived from the
100 MU calibration image has shown a variation of less than 1%.
The resulting MU value can be used in conjunction with log file
based IMRT QA methods to incorporate a “measurement” into the
process. This method was used with the Dynalog QA method
investigated here.
4.B | Dynalog QA
The Dynalog method performed similarly to the Delta4 when using
the 2 SD and ROC derived pass thresholds. Dynalog method did not
have trouble detecting the gantry angle errors but had difficulty
detecting small MLC deviations.
4.C | Delta4
The Delta4 was deficient in detecting gantry angle errors. The Delta4
uses gantry angles supplied in the treatment plan and not the actual
gantry angles and therefore does not recognize gantry angle devia-
tions. The Delta4 was also unsuccessful in detecting small MLC devi-
ations. This is due to the relatively large diode spacing compared to
the magnitude of the MLC errors.
4.D | Dose to PTV
The Dynalog method performed very well when using the dosi-
metric indicators. Where gamma analysis had failed to detect
small MLC deviations, D2 was successful. With this detection
method 11 of the 15 small MLC errors were detected while a
total of seven were caught using gamma analysis: 6 of 15 with
the Delta4, 1 of 15 with the EPID and none with Dynalogs. The
EPID method performed poorly here because of the blurring of
the dose distribution due to scatter radiation. There were large
differences seen in both the original plans as well as with the
error containing plans with the EPID method which made it diffi-
cult to attribute deviations to errors.
4.E | Analysis metrics
Gamma index analysis exhibited poor sensitivity to small errors for
all three IMRT QA methods investigated here. The failure of the
gamma index to detect small errors has been documented and is in
line with our findings.4,6,8,11 Even with optimization using ROC
methods gamma analysis fails to detect MLC errors of less than
~2 mm.14 However, the use of D2 as an additional error detection
metric enhances the capabilities of the systems to detect small
errors as well as reducing the number of false positives that can be
an issue with gamma index analysis.
5 | CONCLUSION
Measurements to established baseline data showed significant differ-
ence in the average gamma values between methods especially for
F I G . 7 . Bar graphs of errors detected by using D2 and D98 of the
PTV.
F I G . 6 . Bar graphs of errors detected by
Dynalog QA at 3%/3 mm, 2%2/ mm, and
1%1 mm.
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stricter gamma index calculation criteria. The baseline data were
used to perform ROC analysis to determine the error detection
capabilities of each patient specific QA method. Our results from all
patient measurements highlighted the strengths and weaknesses of
each method used for patient specific QA in detecting small clinically
relevant errors. It was also evident from the results that the gamma
index as an analysis tool has significant limitations in detecting small
errors as no method investigated here could detect more than 60%
of the intentional errors.
Individually, neither the EPID nor Dynalog method performed as
well as the Delta4 when using the gamma index only. However, a
combination of the two methods (scaling Dynalog doses using EPID
images) matches the detection capabilities of the Delta4. Moreover,
with the scaled Dynaolgs, the plan can be recalculated using the
MLC location information and using the PTV D2 and D98, we were
able to increase the detectability of the errors. The increased sensi-
tivity gained for analysis of dose to the PTV combined with phan-
tom-less data collection makes this method an attractive alternative
to phantom-based patient specific IMRT QA.
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